Evidence map›Paper›PMID 36975649›Full record

ArticleGels (Basel, Switzerland)2023

Pluronic

Pedro Francisco, Mariana Neves Amaral, Afonso Neves, Tânia Ferreira-Gonçalves, Ana S Viana, José Catarino, Pedro Faísca, Sandra Simões, João Perdigão, Adília J Charmier and 2 more

Open access · goldFull text read
In one paragraph

Article in Gels (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. BifunctionalGels (Basel, Switzerland) · 2026
    Article
  2. Naringenin Nanocrystals Containing PluronicGels (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Pedro FranciscoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
Mariana Neves AmaralResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.ORCID 0000-0002-4526-2157
Afonso NevesResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
Tânia Ferreira-GonçalvesResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.ORCID 0000-0001-9916-3907
Ana S VianaCentro de Química Estrutural, Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, 1749-016 Lisbon, Portugal.ORCID 0000-0001-8405-9672
José CatarinoFaculdade de Medicina Veterinária, Universidade Lusoófona de Humanidades e Tecnologias, 1749-024 Lisbon, Portugal.
Pedro FaíscaFaculdade de Medicina Veterinária, Universidade Lusoófona de Humanidades e Tecnologias, 1749-024 Lisbon, Portugal.ORCID 0000-0002-3922-3602
Sandra SimõesResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
João PerdigãoResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.
Adília J CharmierDREAMS, Universidade Lusófona de Humanidades e Tecnologias, Campo Grande 376, 1749-024 Lisbon, Portugal.
M Manuela GasparResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.ORCID 0000-0001-6814-7226
Catarina Pinto ReisResearch Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, 1649-003 Lisbon, Portugal.ORCID 0000-0002-1046-4031
University of Lisbon · PTUniversidade Lusófona · PT

Funding

Fundação para a Ciência e Tecnologia UIDB/04138/2020, UIDP/04138/2020, UIDB/00645/2020, UIDB/00100/2020, SFRH/BD/147306/2019 and SFRH/BD/05377/2021, UIDP/00100/2020, and CEECIND/00394/2017
6 · The paper itself

Abstract

Presently, skin burns are considered one of the main public health problems and lack therapeutic options. In recent years, silver nanoparticles (AgNPs) have been widely studied, playing an increasingly important role in wound healing due to their antibacterial activity. This work is focused on the production and characterization of AgNPs loaded in a Pluronic

Indexed as

burnsnanotechnologysilver nanoparticlestopical administrationwound healing

Identifiers

PMID36975649
PMCPMC10048756
OpenAlexW4323361761

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read36
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.